SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

By | June 30, 2021
In an effort to hasten the research on identifying antiviral drugs for SARS-CoV-2 infection, researchers from the U.S. and Switzerland performed extensive drug screening for antiviral activity using live virus infection in human respiratory cells. As a result, they identified a set of possible drug candidates that could potentially be tested in clinical trials.